← Oncology Approval Tracker

FDA DECISION ·

Inqovi

decitabine + cedazuridine · Astex Pharmaceuticals

FDA approvalNew therapyMyelodysplastic syndromes and chronic myelomonocytic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with myelodysplastic syndromes, including previously treated or untreated, de novo or secondary disease in specified subtypes and intermediate-1, intermediate-2 or high-risk groups, including chronic myelomonocytic leukemia.

LAMPGEN ANALYSIS

Why it matters

Paired decitabine with cedazuridine to make oral decitabine exposure feasible.

What research teams should watch

Plan oral adherence checks and blood counts and avoid interchanging this regimen with IV decitabine mid-cycle.

PRIMARY RECORDS

Sources